- Home
- CGNT vs KROS Comparison
CGNT vs KROS Comparison
Compare CGNT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- KROS
- Stock Information
- Founded
- CGNT 2020
- KROS 2015
- Country
- CGNT Israel
- KROS United States
- Employees
- CGNT 1600
- KROS N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- KROS Health Care
- Exchange
- CGNT Nasdaq
- KROS Nasdaq
- Market Cap
- CGNT 617.3M
- KROS 565.0M
- IPO Year
- CGNT N/A
- KROS 2020
- Fundamental
- Price
- CGNT $8.35
- KROS $15.84
- Analyst Decision
- CGNT Hold
- KROS Buy
- Analyst Count
- CGNT 1
- KROS 14
- Target Price
- CGNT N/A
- KROS $20.56
- AVG Volume (30 Days)
- CGNT 301.1K
- KROS 417.9K
- Earning Date
- CGNT 09-09-2025
- KROS 11-05-2025
- Dividend Yield
- CGNT N/A
- KROS N/A
- EPS Growth
- CGNT N/A
- KROS N/A
- EPS
- CGNT N/A
- KROS 0.47
- Revenue
- CGNT $376,566,000.00
- KROS $232,844,000.00
- Revenue This Year
- CGNT $14.94
- KROS $5,579.44
- Revenue Next Year
- CGNT $9.57
- KROS N/A
- P/E Ratio
- CGNT N/A
- KROS $34.08
- Revenue Growth
- CGNT 14.04
- KROS 85820.30
- 52 Week Low
- CGNT $6.38
- KROS $9.12
- 52 Week High
- CGNT $11.66
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CGNT 43.00
- KROS 60.69
- Support Level
- CGNT $8.27
- KROS $15.34
- Resistance Level
- CGNT $8.81
- KROS $15.85
- Average True Range (ATR)
- CGNT 0.31
- KROS 0.43
- MACD
- CGNT -0.04
- KROS -0.01
- Stochastic Oscillator
- CGNT 13.73
- KROS 73.01
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.